The clinical significance of anti-neutrophil cytoplasmic antibodies in patients with new-onset systemic lupus erythematosus, especially in systemic disease accompanied by interstitial lung disease remains to be elucidated. oBjectives: This study was designed to investigate the role of anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus patients. Methods: A hundred and seven patients with new-onset SLE were enrolled. Presence of anti-neutrophil cytoplasmic antibodies in the sera was assessed by indirect immunofluorescence as well as enzyme linked immunosorbent assay against proteinase-3 and myeloperoxidase. Clinical features and laboratory parameters of patients were also recorded. All patients were subjected to chest X-ray, chest high-resolution computed tomography and pulmonary function test. results: Forty-five systemic lupus erythematosus patients (45/107, 42%) were seropositive for anti-neutrophil cytoplasmic antibodies. Compared with anti-neutrophil cytoplasmic antibodies-negative patients, the anti-neutrophil cytoplasmic antibodies-positive patients had significantly higher incidence of renal involvement, anemia, and Raynaud's phenomenon as well as decreased serum level of complement 3/complement 4 and elevated erythrocyte sedimentation rate. In addition, there was a positive correlation between serum anti-neutrophil cytoplasmic antibodies level and disease activity of systemic lupus erythematosus. Furthermore, prevalence of interstitial lung disease in the anti-neutrophil cytoplasmic antibodies -positive patients (25/45, 55.6%) was obviously higher than that in the anti-neutrophil cytoplasmic antibodies-negative patients (15/62, 24.2%). study liMitations: The sample size was limited and the criteria for screening new-onset systemic lupus erythematosus patients might produce bias. conclusions: The level of anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus patients correlates positively with the disease activity and the prevalence of interstitial lung disease.
INTRODUCTION
Systemic lupus erythematosus (SLE) is one of the most complicated autoimmune diseases, which is characterized by the production of clusters of autoantibodies, the involvement of multiple organs, and a broad spectrum of clinical manifestations. 1 Due to the serological hallmark of abnormal appearance of various autoantibodies in SLE patients, increasing evidence has indicated that the evaluation of clinical relevance between these autoantibodies and disease parameters can help clinicians to identify SLE patients at risk for specific complications at the early stage and expand effective therapeutic strategies. 2, 3 Antineutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies that are directed against specific antigens such as neutrophil cytoplasmic granules and monocyte lysosomes. 4 Since ANCA were first found in the serum from patients with segmental necrotizing glomerulonephritis in 1982, they were soon identified as important serological markers of primary vasculitis. 5 Up to now, the association of ANCA with the small-vessel vasculitis, including Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis, has been well reported. 6 In fact, vasculitis is a well-documented clinical manifestation in SLE patients. Although a host of studies have focused on the relationship between ANCA and SLE, the clinical significance of ANCA in SLE patients remains controversial. Moreover, lung involvement is quite common in SLE, and one of the general pulmonary complications of SLE is interstitial lung disease (ILD). 7 It has been suggested that there is a close relationship between ILD and ANCA-associated vasculitis both pathophysiologically and clinically. 8 However, the possible clinical relevance of ANCA with ILD in SLE patients has not been reported.
In the present study, we investigated ANCA levels of 107 new-onset SLE patients who had never received treatment for SLE.
The possible associations between the presence of ANCA and SLE disease activity, as well as ILD in SLE patients, were also evaluated.
Methods

Study subjects
In a cross-sectional descriptive analytical study, 107 new-onset SLE patients (106 women, one man) were screened from a large number of inpatients with SLE at the Department of Rheumatology Mean disease duration of these new-onset SLE patients was 3.7±1.3
months (2 to 6 months) and mean age was 37.5±9.8 years (range from 16 to 60 years). Samples of sera from all patients were collected. Informed consent from each subject was obtained before enrollment into this study, which was conducted according to the ethical standards of China Medical University. 
Clinical and laboratory assessments
Chest high-resolution computed tomography (HRCT)
HRCT scans of the thorax were performed using a Toshiba spiral CT (scan time 1s, 140mA, 120kV) with images windowed to highlight both lungs and mediastinal structures. the results of HRCT showed that, compared with ANCA-negative group, ANCA-positive SLE patients had higher incidence of common manifestations of ILD, including interlobular septum thickening, ground-glass density, pleural reaction, small tubercle shadow, pericardial effusion, and pulmonary artery hypertension ( Table 2) .
Discussion
The present study was conducted to evaluate the clinical significance of ANCA in new-onset SLE patients. We found that there was a positive correlation between serum ANCA level and the SLE disease activity. Furthermore, we also demonstrated, for the first time, that the incidence of ILD in ANCA-positive patients with new-onset SLE was obviously higher than that in ANCA-negative patients.
Up to date, the clinical significance of ANCA in SLE is still controversial. Some studies report that there is an association between ANCA-positivity and SLE. Manolova et al. found that ANCA were associated with the particular clinical features of SLE and correlated with disease activity. 13 Pradhan et al. also reported that ANCA was positively associated with SLE disease activity, and might be used as a potential complementary parameter to differen-tiate lupus nephritis from SLE without nephritis. 14 On the contrary, others reported no link. Fauzi et al. failed to find significant association between ANCA-positivity and SLE disease activity. 15 Nishiya et al. reported that ANCA was unrelated to organic involvement. 16 Patient selection criteria might be an important factor responsible for these disparities. These previous studies did not exclude patients with a history of immunosuppressants or corticosteroids use, which should have potential influence on the results. Therefore, in this study, only new-onset SLE patients who had never received any treatment for SLE were enrolled. Our findings demonstrated that serum ANCA level significantly correlated with particular clinical features as well as SLE disease activity, suggesting that it may serve as a potential useful parameter for the diagnosis of new-onset SLE.
In this study, we also found that the incidence of ILD in ANCA-positive SLE patients was significantly higher than in AN-CA-negative patients. In ANCA-positive group, ILD was charac- Despite these findings, this investigation presented a few limitations. Indeed, as a cross-sectional descriptive analytical study, the sample size was limited and the ANCA level from some control In addition, although new-onset SLE patients were screened based on three criteria, some information related to the criteria (e.g., duration of disease) was collected from the patients' chart. Therefore, we cannot rule out the bias of new-onset definition.
